All Stories

  1. Real-world thrombotic outcomes in patients with secondary erythrocytosis in comparison with polycythemia vera

    Article • Blood Red Cells & Iron, March 2026, Elsevier

    Dr Alejandro Lazo-Langner

  2. DOACs versus warfarin in AF with comorbid CKD or valvular disease: A systematic review and meta-analysis

    Article • Blood Vessels Thrombosis & Hemostasis, October 2025, Elsevier

    Dr Alejandro Lazo-Langner

  3. Diagnosis, management, and outcomes of drug-induced erythrocytosis: a systematic review

    Article • Blood Advances, April 2025, American Society of Hematology

    Dr Alejandro Lazo-Langner

  4. Are outcomes of locally advanced cervical cancer associated with prebrachytherapy hemoglobin values and transfusion practice? An observational study comparing two large academic centres with divergent clinical guidelines

    Article • Brachytherapy, November 2024, Elsevier

    Dr Alejandro Lazo-Langner

  5. Physician practice patterns on the use of inferior vena cava filters in venous thromboembolism

    Article • Research and Practice in Thrombosis and Haemostasis, August 2024, Elsevier

    Dr Alejandro Lazo-Langner

  6. Serologic Response to Vaccine for COVID-19 in Patients with Hematologic Malignancy: A Prospective Cohort Study

    Article • Clinical Lymphoma Myeloma & Leukemia, May 2024, Elsevier

    Dr Alejandro Lazo-Langner

  7. Myelodysplastic Neoplasms (MDS) with Ring Sideroblasts or SF3B1 Mutations: The Improved Clinical Utility of World Health Organization and International Consensus Classification 2022 Definitions, a Single-Centre Retrospective Chart Review

    Article • Current Oncology, March 2024, MDPI AG

    Dr Alejandro Lazo-Langner

  8. Comparing DOACs with warfarin in AF patients with chronic kidney disease or valvular disease: A systematic review and meta-analysis

    Article • January 2024, Cold Spring Harbor Laboratory Press

    Dr Alejandro Lazo-Langner

  9. An Approach to the Investigation of Thrombocytosis: Differentiating between Essential Thrombocythemia and Secondary Thrombocytosis

    Article • Advances in Hematology, January 2024, Wiley

    Dr Alejandro Lazo-Langner

  10. Thrombosis and coagulopathy in COVID-19: A current narrative

    Article • January 2024, Elsevier

    Dr Alejandro Lazo-Langner

  11. Anticoagulant prophylaxis in pregnant women with a history of venous thromboembolism: A systematic review and meta-analysis

    Article • Thrombosis Update, December 2023, Elsevier

    Dr Alejandro Lazo-Langner

  12. Outpatient consolidation chemotherapy with intermediate dose cytarabine has similar survival and relapses rates in acute myeloid leukemia as compared to high dose cytarabine: A single center analysis

    Article • European Journal Of Haematology, August 2023, Wiley

    Dr Alejandro Lazo-Langner

  13. Risk of venous thromboembolism or hemorrhage among individuals with chronic kidney disease on prophylactic anticoagulant after hip or knee arthroplasty

    Article • American Journal of Hematology, June 2023, Wiley

    Dr Alejandro Lazo-Langner

  14. Venous thromboembolism in hematopoietic stem cell transplantation: A narrative review

    Article • Thrombosis Research, June 2023, Elsevier

    Dr Alejandro Lazo-Langner

  15. The risk of major bleeding in patients with factor V Leiden or prothrombin G20210A gene mutation while on extended anticoagulant treatment for venous thromboembolism

    Article • Journal of Thrombosis and Haemostasis, March 2023, Elsevier

    Dr Alejandro Lazo-Langner

  16. Anticoagulation strategies and outcomes during extracorporeal membrane oxygenation support: a single-centre pre-COVID-19 experience

    Article • Canadian Journal of Anesthesia/Journal canadien d anesthésie, January 2023, Springer Science + Business Media

    Dr Alejandro Lazo-Langner

  17. A Rational Approach to JAK2 Mutation Testing in Patients with Elevated Hemoglobin: Results from the JAK2 Prediction Cohort (JAKPOT) Study

    Article • Journal of General Internal Medicine, November 2022, Springer Science + Business Media

    Dr Alejandro Lazo-Langner

  18. The Impact of Artificial Intelligence on Health Equity in Oncology: Scoping Review

    Article • Journal of Medical Internet Research, November 2022, JMIR Publications Inc.

    Dr Alejandro Lazo-Langner

  19. Secondary causes of elevated hemoglobin in patients undergoing molecular testing for suspected polycythemia vera in southwestern Ontario: a chart review

    Article • CMAJ Open, October 2022, Canadian Medical Association (CMA)

    Dr Alejandro Lazo-Langner

  20. Which are the optimal thromboprophylaxis strategies for hospitalized patients with COVID-19? current controversies

    Article • Vascular, September 2022, SAGE Publications

    Dr Alejandro Lazo-Langner

  21. Predicting major bleeding during extended anticoagulation for unprovoked or weakly provoked venous thromboembolism

    Article • Blood Advances, August 2022, American Society of Hematology

    Dr Alejandro Lazo-Langner

  22. Venous and Arterial Thrombosis in Ambulatory and Discharged COVID-19 Patients: A Systematic Review and Meta-analysis

    Article • TH Open, July 2022, Thieme Publishing Group

    Dr Alejandro Lazo-Langner

  23. Clinical characteristics, multiorgan dysfunction and outcomes of patients with COVID-19: a prospective case series

    Article • CMAJ Open, July 2022, Canadian Medical Association (CMA)

    Dr Alejandro Lazo-Langner

  24. Thromboprophylaxis Strategies for Hospitalized Patients With COVID-19

    Article • CHEST Journal, July 2022, Elsevier

    Dr Alejandro Lazo-Langner

  25. Rivaroxaban for the treatment of noncirrhotic splanchnic vein thrombosis: an interventional prospective cohort study

    Article • Blood Advances, June 2022, American Society of Hematology

    Dr Alejandro Lazo-Langner

  26. Thrombolysis in the recovery of coagulated bone marrow aspirate samples

    Article • International Journal of Laboratory Hematology, May 2022, Wiley

    Dr Alejandro Lazo-Langner

  27. Association between genetic mutations and risk of venous thromboembolism in patients with solid tumor malignancies: A systematic review and meta-analysis

    Article • Thrombosis Research, May 2022, Elsevier

    Dr Alejandro Lazo-Langner

  28. Drug reaction with eosinophilia and systemic symptoms (DRESS): A tertiary care centre retrospective study

    Article • British Journal of Clinical Pharmacology, April 2022, Wiley

    Dr Alejandro Lazo-Langner

  29. The impact of red blood cell transfusion on mortality and treatment efficacy in patients treated with radiation: A systematic review

    Article • Clinical and Translational Radiation Oncology, March 2022, Elsevier

    Dr Alejandro Lazo-Langner

  30. Diagnosis of deep vein thrombosis with D-dimer adjusted to clinical probability: prospective diagnostic management study

    Article • BMJ, February 2022, BMJ

    Dr Alejandro Lazo-Langner

  31. Treatment of retinal vein thrombosis: what about anticoagulants?

    Article • Minerva Medica, February 2022, Edizioni Minerva Medica

    Dr Alejandro Lazo-Langner

  32. Serum erythropoietin levels in 696 patients investigated for erythrocytosis with JAK2 mutation analysis

    Article • American Journal of Hematology, January 2022, Wiley

    Dr Alejandro Lazo-Langner

  33. Risk for Recurrent Venous Thromboembolism in Patients With Subsegmental Pulmonary Embolism Managed Without Anticoagulation

    Article • Annals of Internal Medicine, January 2022, American College of Physicians

    Dr Alejandro Lazo-Langner

  34. Unexplained anemia of aging: Etiology, health consequences, and diagnostic criteria

    Article • Journal of the American Geriatrics Society, November 2021, Wiley

    Dr Alejandro Lazo-Langner

  35. Reducing cytogenetic testing in the era of next generation sequencing: Are we choosing wisely?

    Article • International Journal of Laboratory Hematology, October 2021, Wiley

    Dr Alejandro Lazo-Langner

  36. Use of serology immunoassays for predicting SARS-CoV-2 infection: a serology-based diagnostic algorithm

    Article • October 2021, Cold Spring Harbor Laboratory Press

    Dr Alejandro Lazo-Langner

  37. MUFFIN-PTS trial, Micronized Purified Flavonoid Fraction for the Treatment of Post-Thrombotic Syndrome: protocol of a randomised controlled trial

    Article • BMJ Open, September 2021, BMJ

    Dr Alejandro Lazo-Langner

  38. APTT therapeutic range for monitoring unfractionated heparin therapy. Significant impact of the anti‐Xa reagent used for correlation: COMMENT

    Article • Journal of Thrombosis and Haemostasis, August 2021, Elsevier

    Dr Alejandro Lazo-Langner

  39. Venous Thromboembolism in Hospitalized Critical and Noncritical COVID-19 Patients: A Systematic Review and Meta-analysis

    Article • TH Open, July 2021, Thieme Publishing Group

    Dr Alejandro Lazo-Langner

  40. COVID-19 vaccine-induced immune thrombotic thrombocytopenia: An emerging cause of splanchnic vein thrombosis

    Article • Annals of Hepatology, July 2021, Elsevier

    Dr Alejandro Lazo-Langner

  41. Postoperative low molecular weight heparin bridging treatment for patients at high risk of arterial thromboembolism (PERIOP2): double blind randomised controlled trial

    Article • BMJ, June 2021, BMJ

    Dr Alejandro Lazo-Langner

  42. Splanchnic vein thrombosis: Clinical manifestations, risk factors, management, and outcomes

    Article • Thrombosis Research, June 2021, Elsevier

    Dr Alejandro Lazo-Langner

  43. A case of congenital prothrombin deficiency with two concurrent mutations in the prothrombin gene

    Article • Research and Practice in Thrombosis and Haemostasis, May 2021, Elsevier

    Dr Alejandro Lazo-Langner

  44. Paediatric serum sickness-like reaction: A 10-year retrospective cohort study

    Article • Paediatrics & Child Health, April 2021, Oxford University Press (OUP)

    Dr Alejandro Lazo-Langner

  45. Current estimates of the incidence of acute venous thromboembolic disease in Canada: A meta-analysis

    Article • Thrombosis Research, January 2021, Elsevier

    Dr Alejandro Lazo-Langner

  46. Development and implementation of common data elements for venous thromboembolism research: on behalf of SSC Subcommittee on official Communication from the SSC of the ISTH

    Article • Journal of Thrombosis and Haemostasis, January 2021, Elsevier

    Dr Alejandro Lazo-Langner

  47. Establishing diagnostic criteria and treatment of subsegmental pulmonary embolism: A Delphi analysis of experts

    Article • Research and Practice in Thrombosis and Haemostasis, November 2020, Elsevier

    Dr Alejandro Lazo-Langner, Luis Jara-Palomares

  48. Thrombophilia testing in patients receiving rivaroxaban or apixaban for the treatment of venous thromboembolism

    Article • Thrombosis Research, November 2020, Elsevier

    Dr Alejandro Lazo-Langner

  49. Long term monitoring of patients with positive lupus anticoagulant and antiphospholipid antibodies. Are all cases persistently positive?

    Article • Thrombosis Research, October 2020, Elsevier

    Dr Alejandro Lazo-Langner

  50. Thrombosis risk associated with COVID-19 infection. A scoping review

    Article • Thrombosis Research, August 2020, Elsevier

    Dr Alejandro Lazo-Langner

  51. Bleeding Risk in Nonvalvular Atrial Fibrillation Patients Receiving Direct Oral Anticoagulants and Warfarin: A Systematic Review and Meta-Analysis of Observational Studies

    Article • TH Open, July 2020, Thieme Publishing Group

    Dr Alejandro Lazo-Langner

  52. Anabolic steroids in myelodysplastic syndromes: A systematic review

    Article • Leukemia Research, July 2020, Elsevier

    Dr Alejandro Lazo-Langner

  53. Clinical value of next‐generation sequencing compared to cytogenetics in patients with suspected myelodysplastic syndrome

    Article • British Journal of Haematology, June 2020, Wiley

    Dr Alejandro Lazo-Langner

  54. Development of a Clinical Prediction Rule for Venous Thromboembolism in Patients with Acute Leukemia

    Article • Thrombosis and Haemostasis, January 2020, Thieme Publishing Group

    Dr Alejandro Lazo-Langner

  55. Efficacy and safety of four-factor prothrombin complex concentrate fixed, weight-based dosing for reversal of warfarin anticoagulation

    Article • Hematology, January 2020, Taylor & Francis

    Dr Alejandro Lazo-Langner

  56. Diagnosis of Pulmonary Embolism with d -Dimer Adjusted to Clinical Probability

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, November 2019, New England Journal of Medicine (NEJM/MMS)

    Dr Alejandro Lazo-Langner

  57. Implementation of an NGS‐based sequencing and gene fusion panel for clinical screening of patients with suspected hematologic malignancies

    Article • European Journal Of Haematology, July 2019, Wiley

    Dr Alejandro Lazo-Langner

  58. Studies in upper extremity deep vein thrombosis: Addressing the knowledge gaps

    Article • Research and Practice in Thrombosis and Haemostasis, July 2019, Elsevier

    Dr Alejandro Lazo-Langner

  59. Treatment of venous thromboembolism in acute leukemia: A systematic review

    Article • Thrombosis Research, June 2019, Elsevier

    Dr Alejandro Lazo-Langner

  60. Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update

    Article • Journal of Clinical Oncology, May 2019, American Society of Clinical Oncology (ASCO)

    Dr Alejandro Lazo-Langner

  61. Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update

    Article • Blood Advances, April 2019, American Society of Hematology

    Dr Alejandro Lazo-Langner, Dr Massimo Martino

  62. Apixaban to Prevent Venous Thromboembolism in Patients with Cancer

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, February 2019, New England Journal of Medicine (NEJM/MMS)

    Dr Alejandro Lazo-Langner

  63. A Case of SF3B1-Positive Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis

    Article • Turkish Journal of Hematology, February 2019, Journal of Clinical Research of Pediatric Endocrinology

    Dr Alejandro Lazo-Langner

  64. Post-thrombotic syndrome and recurrent thromboembolism in patients with upper extremity deep vein thrombosis: A systematic review and meta-analysis

    Article • Thrombosis Research, February 2019, Elsevier

    Dr Alejandro Lazo-Langner

  65. Large expert-curated database for benchmarking document

    Article • Database, January 2019, Oxford University Press (OUP)

    Dr Daniel Prieto, Associate Professor James A.L. Brown, Professor Amanda G Thrift, Docent Kutty Selva Nandakumar, Professor Miguel Viveiros, MD Diego A. Valera-Cornejo, Dr Soroush Safaei, Dr Carmen San Martín, Piero Carninci, Dr Florian Rehfeldt, Dr Yoichi Watanabe, Kazuki Ide, Mr Alvin Wong, PD Dr. Adrian Meule, Dr Maurizio Petrelli, Dr Christine McGarrigle, Dr Tristan Reddan, Dr Nicola Roberts, Professor Stefan Lorkowski, Dr Cyrille Goarant, Dr Emma C Hobbs, Dr. Saurab Sharma, Ph.D., Dr Farid Rahimi, Prof. Iseult Lynch, Mirella Walker, Dr Luca Galluzzi, Sophie Ohlsson, Professor Tullio Florio, Dr Rabea A Gadelkareem, Dr Azubuike Christian Ukubuiwe, Prof Gajendra PS Raghava, Prof Jun Shen, Lubna Razak, ABHISHEKA BANSAL, Craig Billington, Dr Alejandro Lazo-Langner, Joan Albiol, MOURAD TAYEBI, Chuang Ma, Christine Toelzer , Dr. Kathrin Karsay, Professor Andrew M Beale, Professor Hugh James Byrne, Dr Ugo Marzocchi, Ana Nordberg, Martin Bartas, Natalia Echeverría, Dr Patricia M Graves, Dr Elvis A F Martis, Dr marco cascella, Dr. Giuseppe Lanza, Dr Michael Boah

  66. Distribution of lymphomas in Mexico: a multicenter descriptive study

    Article • Journal of Hematopathology, December 2018, Springer Science + Business Media

    Dr Alejandro Lazo-Langner

  67. Erratum to: Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study

    Article • Thrombosis and Haemostasis, November 2018, Thieme Publishing Group

    Dr Alejandro Lazo-Langner

  68. A matched case-control study to assess the association between non-steroidal anti-inflammatory drug use and thrombotic microangiopathy

    Article • PLOS One, August 2018, PLOS

    Dr Alejandro Lazo-Langner

  69. Immigration, region of origin, and the epidemiology of venous thromboembolism: A population‐based study

    Article • Research and Practice in Thrombosis and Haemostasis, July 2018, Elsevier

    Dr Alejandro Lazo-Langner

  70. Prevention of venous thromboembolism in pregnant patients with a history of venous thromboembolic disease: A retrospective cohort study

    Article • Thrombosis Research, July 2018, Elsevier

    Dr Alejandro Lazo-Langner

  71. Standardization of extracellular vesicle measurements by flow cytometry through vesicle diameter approximation

    Article • Journal of Thrombosis and Haemostasis, June 2018, Elsevier

    Dr Alejandro Lazo-Langner

  72. Adherence to, and Outcomes of, a Galactomannan Screening Protocol in High-Risk Hematology Patients

    Article • Current Oncology, April 2018, MDPI AG

    Dr Alejandro Lazo-Langner

  73. Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study

    Article • Thrombosis and Haemostasis, March 2018, Thieme Publishing Group

    Dr Alejandro Lazo-Langner

  74. A prospective study of Rivaroxaban for central venous catheter associated upper extremity deep vein thrombosis in cancer patients (Catheter 2)

    Article • Thrombosis Research, February 2018, Elsevier

    Dr Alejandro Lazo-Langner

  75. Systematic review of azacitidine regimens in myelodysplastic syndrome and acute myeloid leukemia

    Article • BMC Hematology, January 2018, Springer Science + Business Media

    Dr Alejandro Lazo-Langner

  76. Health-related quality of life in children with cutaneous adverse drug reactions

    Article • Pediatric Dermatology, September 2017, Wiley

    Dr Alejandro Lazo-Langner

  77. Erythropoiesis-stimulating agents in elderly patients with anemia: response and cardiovascular outcomes

    Article • Blood Advances, August 2017, American Society of Hematology

    Dr Alejandro Lazo-Langner

  78. Cost effectiveness of the addition of a comprehensive CT scan to the abdomen and pelvis for the detection of cancer after unprovoked venous thromboembolism

    Article • Thrombosis Research, March 2017, Elsevier

    Dr Alejandro Lazo-Langner

  79. Blood donation and testosterone replacement therapy

    Article • Transfusion, February 2017, Wiley

    Dr Alejandro Lazo-Langner

  80. Impact of thrombophilia screening on venous thromboembolism management practices

    Article • Thrombosis Research, January 2017, Elsevier

    Dr Alejandro Lazo-Langner

  81. Retinal vein thrombosis: The Internist's role in the etiologic and therapeutic management

    Article • Thrombosis Research, December 2016, Elsevier

    Dr Alejandro Lazo-Langner

  82. eculizumab in PNH

    Article • Therapeutics and Clinical Risk Management, August 2016, Dove Medical Press

    Dr. Fatimah FA Al-Ani, Dr Alejandro Lazo-Langner

  83. A multicenter prospective study of risk factors and treatment of unusual site thrombosis

    Article • Thrombosis Research, August 2016, Elsevier

    Dr Alejandro Lazo-Langner

  84. Erythropoietin Levels in Elderly Patients with Anemia of Unknown Etiology

    Article • PLOS One, June 2016, PLOS

    Dr Alejandro Lazo-Langner

  85. Risk factors predictive of occult cancer detection in patients with unprovoked venous thromboembolism

    Article • Blood, April 2016, American Society of Hematology

    Dr Alejandro Lazo-Langner

  86. Randomized double-blind safety comparison of intravenous iron dextran versus iron sucrose in an adult non-hemodialysis outpatient population: A feasibility study

    Article • BMC Hematology, March 2016, Springer Science + Business Media

    Dr Alejandro Lazo-Langner

  87. Erythropoietin in anemia of unknown etiology: A systematic review and meta-analysis

    Article • Hematology, January 2016, Taylor & Francis

    Dr Alejandro Lazo-Langner

  88. Guidance for the management of venous thrombosis in unusual sites

    Article • Journal of Thrombosis and Thrombolysis, January 2016, Springer Science + Business Media

    Dr Alejandro Lazo-Langner

  89. The effect of low-dose oral vitamin K supplementation on INR stability in patients receiving warfarin

    Article • Thrombosis and Haemostasis, January 2016, Thieme Publishing Group

    Dr Alejandro Lazo-Langner

  90. Identifying venous thromboembolism and major bleeding in emergency room discharges using administrative data

    Article • Thrombosis Research, December 2015, Elsevier

    Dr Alejandro Lazo-Langner

  91. Association between inflammation biomarkers, anatomic extent of deep venous thrombosis, and venous symptoms after deep venous thrombosis

    Article • Journal of Vascular Surgery Venous and Lymphatic Disorders, October 2015, Elsevier

    Dr Alejandro Lazo-Langner

  92. Review: In AF or VTE, direct oral anticoagulants reduce fatal bleeding compared with vitamin K antagonists

    Article • Annals of Internal Medicine, October 2015, American College of Physicians

    Dr Alejandro Lazo-Langner

  93. Screening for Occult Cancer in Unprovoked Venous Thromboembolism

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, August 2015, New England Journal of Medicine (NEJM/MMS)

    Dr Alejandro Lazo-Langner

  94. Quality of life in children with adverse drug reactions: a narrative and systematic review

    Article • British Journal of Clinical Pharmacology, July 2015, Wiley

    Dr Alejandro Lazo-Langner

  95. Screening of Patients with Idiopathic Venous Thromboembolism for Paroxysmal Nocturnal Hemoglobinuria Clones

    Article • Thrombosis Research, June 2015, Elsevier

    Dr Alejandro Lazo-Langner

  96. Inflammation markers and their trajectories after deep vein thrombosis in relation to risk of post-thrombotic syndrome

    Article • Journal of Thrombosis and Haemostasis, February 2015, Wiley

    Dr Alejandro Lazo-Langner

  97. Fondaparinux for the treatment of suspected heparin-induced thrombocytopenia: a propensity score–matched study

    Article • Blood, February 2015, American Society of Hematology

    Dr Alejandro Lazo-Langner

  98. Clinical Challenges in Patients with Cancer-Associated Thrombosis: Canadian Expert Consensus Recommendations

    Article • Current Oncology, February 2015, MDPI AG

    Dr Alejandro Lazo-Langner

  99. Response to “Need to Minimize Bias When Surveying Patient Attitudes to Stopping cml Treatment”

    Article • Current Oncology, December 2014, MDPI AG

    Dr Alejandro Lazo-Langner

  100. Rivaroxaban vs. low molecular weight heparin for the prevention of venous thromboembolism after hip or knee arthroplasty: a cohort study

    Article • Journal of Thrombosis and Haemostasis, October 2014, Elsevier

    Dr Alejandro Lazo-Langner

  101. The effect of low molecular weight heparin on survival in cancer patients: an updated systematic review and meta‐analysis of randomized trials: reply

    Article • Journal of Thrombosis and Haemostasis, September 2014, Elsevier

    Dr Alejandro Lazo-Langner

  102. Genetic polymorphisms of vein wall remodeling in chronic venous disease: a narrative and systematic review

    Article • Blood, August 2014, American Society of Hematology

    Dr Alejandro Lazo-Langner

  103. The effect of low molecular weight heparin on survival in cancer patients: an updated systematic review and meta‐analysis of randomized trials

    Article • Journal of Thrombosis and Haemostasis, July 2014, Elsevier

    Dr Alejandro Lazo-Langner

  104. Patient preferences for stopping tyrosine kinase inhibitors in chronic myeloid leukemia

    Article • Current Oncology, April 2014, MDPI AG

    Dr Alejandro Lazo-Langner

  105. Acute myeloid leukemia relapse first presenting in the cerebrospinal fluid

    Article • Blood, January 2014, American Society of Hematology

    Dr Alejandro Lazo-Langner

  106. Initial Management of Noncirrhotic Splanchnic Vein Thrombosis: When Is Anticoagulation Enough?

    Article • Canadian Journal of Gastroenterology and Hepatology, January 2014, Hindawi Publishing Corporation

    Dr Alejandro Lazo-Langner

  107. Effect of anticoagulants and antiplatelet agents on the efficacy of intravesical BCG treatment of bladder cancer: A systematic review

    Article • Canadian Urological Association Journal, November 2013, Canadian Urological Association Journal

    Dr Alejandro Lazo-Langner

  108. Clinical performance of bleeding risk scores for predicting major and clinically relevant non‐major bleeding events in patients receiving warfarin

    Article • Journal of Thrombosis and Haemostasis, September 2013, Elsevier

    Dr Alejandro Lazo-Langner

  109. The equipoise of perioperative anticoagulation management: a Canadian cross-sectional survey

    Article • Journal of Thrombosis and Thrombolysis, July 2013, Springer Science + Business Media

    Dr Alejandro Lazo-Langner

  110. Predictors of unsuccessful mobilization with granulocyte colony‐stimulating factor alone in patients undergoing autologous hematopoietic stem cell transplantation

    Article • Journal of Clinical Apheresis, February 2013, Wiley

    Dr Alejandro Lazo-Langner

  111. Cisplatin and Short-Term 5-Fluorouracil Infusion for Paraneoplastic Microangiopathic Hemolytic Anemia in Gastric Cancer: A Case Report and Review of the Literature

    Article • Case Reports in Oncological Medicine, January 2013, Hindawi Publishing Corporation

    Dr Alejandro Lazo-Langner

  112. Kidney and Pancreatic Extramedullary Relapse in Adult Acute Lymphoblastic Leukemia: A Case Report and Review of the Literature

    Article • Case Reports in Hematology, January 2013, Wiley

    Dr Alejandro Lazo-Langner

  113. Spontaneous Retroperitoneal Hemorrhage in a Patient with Prolymphocytic Transformation of Chronic Lymphocytic Leukemia

    Article • Case Reports in Hematology, January 2013, Wiley

    Dr Alejandro Lazo-Langner

  114. Cardiac Conduction Block at Multiple Levels Caused by Arsenic Trioxide Therapy

    Article • Canadian Journal of Cardiology, January 2013, Elsevier

    Dr Alejandro Lazo-Langner

  115. Clinical review: Clinical management of new oral anticoagulants: a structured review with emphasis on the reversal of bleeding complications

    Article • Critical Care, January 2013, Springer Science + Business Media

    Dr Alejandro Lazo-Langner

  116. Myelodyspastic syndrome with complex cytogenetics

    Article • Blood, November 2012, American Society of Hematology

    Dr Alejandro Lazo-Langner

  117. New oral anticoagulants

    Article • Canadian Medical Association Journal, November 2012, Canadian Medical Association (CMA)

    Dr Alejandro Lazo-Langner

  118. Conservative perioperative anticoagulation management in patients with chronic venous thromboembolic disease: a cohort study

    Article • Journal of Thrombosis and Haemostasis, November 2012, Elsevier

    Dr Alejandro Lazo-Langner

  119. Histoplasmosis-induced pancytopenia

    Article • Blood, October 2012, American Society of Hematology

    Dr Alejandro Lazo-Langner

  120. Development of a Clinical Prediction Rule for Risk Stratification of Recurrent Venous Thromboembolism in Patients With Cancer-Associated Venous Thromboembolism

    Article • Circulation, July 2012, Wolters Kluwer Health

    Dr Alejandro Lazo-Langner

  121. Acute myeloid leukemia with promyelocytic morphology lacking RARA rearrangement and with double minutes, MYC deletion and 2 cell lines with amplification of MYC region: case report and literature review

    Article • Journal of Hematopathology, July 2012, Springer Science + Business Media

    Dr Alejandro Lazo-Langner

  122. Acute nonlymphocytic leukemia presenting with pancytopenia

    Article • Blood, February 2012, American Society of Hematology

    Dr Alejandro Lazo-Langner

  123. Comparing multiple competing interventions in the absence of randomized trials using clinical risk-benefit analysis

    Article • BMC Medical Research Methodology, January 2012, Springer Science + Business Media

    Dr Alejandro Lazo-Langner

  124. Bleeding risk assessment during oral anticoagulant therapy initiation

    Article • Expert Review of Hematology, January 2012, Taylor & Francis

    Dr Alejandro Lazo-Langner

  125. Study of Octaplex dosing accuracy: An in vitro analysis

    Article • Thrombosis and Haemostasis, January 2012, Thieme Publishing Group

    Dr Alejandro Lazo-Langner

  126. Clinical and Genetic Determinants of Warfarin Pharmacokinetics and Pharmacodynamics during Treatment Initiation

    Article • PLOS One, November 2011, PLOS

    Dr Alejandro Lazo-Langner

  127. Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy

    Article • Blood, September 2011, American Society of Hematology

    Dr Alejandro Lazo-Langner

  128. Treatment of Hodgkin lymphoma with adriamycin, bleomycin, vinblastine and dacarbazine without routine granulocyte-colony stimulating factor support does not increase the risk of febrile neutropenia: a prospective cohort study

    Article • Leukemia & Lymphoma, August 2011, Taylor & Francis

    Dr Alejandro Lazo-Langner

  129. More on: lupus anticoagulant testing during acute thrombotic events

    Article • Journal of Thrombosis and Haemostasis, August 2011, Elsevier

    Dr Alejandro Lazo-Langner

  130. The pandemic H1N1 influenza vaccine results in low rates of seroconversion for patients with hematological malignancies

    Article • Leukemia & Lymphoma, June 2011, Taylor & Francis

    Dr Alejandro Lazo-Langner

  131. Retinal-Vein Occlusion

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, March 2011, New England Journal of Medicine (NEJM/MMS)

    Dr Alejandro Lazo-Langner

  132. Retinal vein thrombosis: pathogenesis and management: a rebuttal

    Article • Journal of Thrombosis and Haemostasis, February 2011, Elsevier

    Dr Alejandro Lazo-Langner

  133. Successful Intraoperative Reversal of Heparin with Factor VII in a Patient with Protamine Reaction

    Article • Innovations Technology and Techniques in Cardiothoracic and Vascular Surgery, January 2011, SAGE Publications

    Dr Alejandro Lazo-Langner

  134. The attitude of Canadian university students toward a behavior‐based blood donor health assessment questionnaire

    Article • Transfusion, December 2010, Wiley

    Dr Alejandro Lazo-Langner

  135. Ambulatory management of pulmonary embolism: a pragmatic evaluation

    Article • Journal of Thrombosis and Haemostasis, November 2010, Elsevier

    Dr Alejandro Lazo-Langner

  136. Anticoagulant response after dalteparin overdose

    Article • Journal of Thrombosis and Haemostasis, October 2010, Elsevier

    Dr Alejandro Lazo-Langner

  137. Predicting warfarin dose

    Article • Current Opinion in Pulmonary Medicine, September 2010, Wolters Kluwer Health

    Dr Alejandro Lazo-Langner

  138. Ultrastructural changes and immunolocalization of P-selectin in platelets from patients with major depression

    Article • Psychiatry Research, April 2010, Elsevier

    Dr Alejandro Lazo-Langner

  139. Low molecular weight heparin for the treatment of retinal vein occlusion: a systematic review and meta-analysis of randomized trials

    Article • Haematologica, March 2010, Ferrata Storti Foundation (Haematologica)

    Dr Alejandro Lazo-Langner

  140. Cutaneous adult T-cell lymphoma leukemia

    Article • Blood, January 2010, American Society of Hematology

    Dr Alejandro Lazo-Langner

  141. Normal levels of protein C and protein S tested in the acute phase of a venous thromboembolic event are not falsely elevated

    Article • Thrombosis Journal, January 2010, Springer Science + Business Media

    Dr Alejandro Lazo-Langner

  142. Predicting warfarin maintenance dose in patients with venous thromboembolism based on the response to a standardized warfarin initiation nomogram

    Article • Journal of Thrombosis and Haemostasis, August 2009, Elsevier

    Dr Alejandro Lazo-Langner

  143. A 10 mg warfarin initiation nomogram is safe and effective in outpatients starting oral anticoagulant therapy for venous thromboembolism

    Article • Thrombosis Research, July 2009, Elsevier

    Dr Alejandro Lazo-Langner

  144. Overview of Current Venous Thromboembolism Protocols in Hip Reconstruction

    Article • Orthopedic Clinics of North America, July 2009, Elsevier

    Dr Alejandro Lazo-Langner

  145. Lessons From Ximelagatran: Issues for Future Studies Evaluating New Oral Direct Thrombin Inhibitors for Venous Thromboembolism Prophylaxis in Orthopedic Surgery

    Article • Clinical and Applied Thrombosis/Hemostasis, November 2008, SAGE Publications

    Dr Alejandro Lazo-Langner

  146. Intrahospital Correlation of the International Normalized Ratio

    Article • Clinical and Applied Thrombosis/Hemostasis, April 2008, SAGE Publications

    Dr Alejandro Lazo-Langner

  147. Long‐term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial

    Article • Journal of Thrombosis and Haemostasis, August 2007, Elsevier

    Dr Alejandro Lazo-Langner

  148. The effect of low‐molecular‐weight heparin on cancer survival. A systematic review and meta‐analysis of randomized trials

    Article • Journal of Thrombosis and Haemostasis, April 2007, Elsevier

    Dr Alejandro Lazo-Langner

  149. The risk of dialysis access thrombosis is related to the transforming growth factor–β1 production haplotype and is modified by polymorphisms in the plasminogen activator inhibitor–type 1 gene

    Article • Blood, December 2006, American Society of Hematology

    Dr Alejandro Lazo-Langner

  150. Moderate and severe neutropenia in patients with systemic lupus erythematosus

    Article • Rheumatology, February 2006, Oxford University Press (OUP)

    Dr Alejandro Lazo-Langner

  151. Contraceptive options for women with factor V leiden

    Article • Journal of Midwifery & Women s Health, May 2004, Wiley

    Dr Alejandro Lazo-Langner

  152. Methodologic pitfalls in measurement of 5-hydroxytriptamine uptake transporters in human platelets by [3H]-paroxetine binding assay

    Article • Archives of Medical Research, September 2003, Elsevier

    Dr Alejandro Lazo-Langner

  153. Platelet satellitism, spurious neutropenia, and cutaneous vasculitis: Casual or causal association?

    Article • American Journal of Hematology, June 2002, Wiley

    Dr Alejandro Lazo-Langner

  154. Effect of all‐trans‐Retinoic acid on the hypercoagulable state of patients with breast cancer

    Article • American Journal of Hematology, April 2002, Wiley

    Dr Alejandro Lazo-Langner

  155. Serum hyperviscosity syndrome responding to therapeutic plasmapheresis in a patient with primary Sjögren's syndrome

    Article • Journal of Clinical Apheresis, January 2002, Wiley

    Dr Alejandro Lazo-Langner

  156. The effects of three different LDL‐apheresis methods on the plasma concentrations of E‐selectin, VCAM‐1, and ICAM‐1

    Article • Journal of Clinical Apheresis, January 2002, Wiley

    Dr Alejandro Lazo-Langner